Published on
13:29 GMT
Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change
When the CEO of a major pharmaceutical company steps down, the transition often comes at a time of reinvention. While many factors play into a decision to shuffle the C-suite, Big Pharma has seen turnover in the last few years as a result of looming patent …
Source:
PharmaVoice
-
Neutral
